ANXA3 and non-small cell lung carcinoma: Our previous study showed that CAFs contribute to cisplatin resistance via modulating ANXA3 in NSCLC cells 10, however, the role of CAFs in the resistance of NSCLC cell to osimertinib remains largely unknown.